98%
921
2 minutes
20
Gastroparesis or gastric stasis is the delayed transit of the ingested contents through the stomach in the absence of mechanical obstruction. It can have multiple etiologies, most commonly idiopathic (ID) and diabetic (DM). Gastroparesis can cause significant distress to patients as it leads to symptoms like intractable nausea and vomiting, weight loss, abdominal bloating, early satiety, etc. The pathogenesis is mainly thought to be due to the dysfunction of the gastric pacemaker cells, i.e., interstitial cells of Cajal (ICC), and their interaction with the other gastric motor function regulatory components. There are several proposed treatment options for gastroparesis. Despite that, most patients remain refractory to medical treatment and require additional interventions for symptomatic relief. One such intervention is gastric electrical stimulation or gastric pacemaker, which aids in improving gastric motility. We have searched PubMed, PubMed Central (PMC), Medline, Science Direct, and Google Scholar for articles pertaining to the use of gastric electrical stimulation in gastroparesis published in the last 10 years. The keywords used include "gastroparesis", "gastric stasis", "gastric pacemaker'', "gastric electrical stimulation", "nausea", "vomiting", "abdominal bloating", "gastric neuromodulation". We have finally included twelve studies that were the most relevant to our research question and met the quality assessment criteria. Exclusion criteria consisted of pediatric population studies, studies conducted on animals, books, and grey literature. Overall, these twelve studies helped evaluate the impact of gastric pacemakers on symptoms of gastroparesis like nausea, vomiting, weight loss, abdominal bloating, and quality of life. We found that most studies favored gastric pacemakers, improving the incidence of nausea and vomiting in patients with gastroparesis. There was a marked improvement in the BMI as well. On the other hand, most open-labeled studies showed improved quality of life and Gastroparesis Cardinal Symptom Index (GCSI) scores, while randomized controlled trials and meta-analyses did not reflect the same result. In addition, some other parameters improved with gastric pacemakers, Inflammatory markers, insulin levels (especially in diabetics), and the number of hospitalizations. In conclusion, gastric pacemaker is a potential treatment option for patients with medically refractory gastroparesis. As noted from the results of our study, nausea/vomiting, weight loss, and overall GCSI scores have shown marked improvement with gastric electrical stimulation (GES). Nevertheless, more extensive research is needed to understand better the full extent of this device's use as a viable treatment option for patients suffering from gastroparesis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457417 | PMC |
http://dx.doi.org/10.7759/cureus.18152 | DOI Listing |
JTCVS Tech
August 2025
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Objective: To evaluate the early outcomes of a modified bio-Bentall operation using a rapid deployment valve (RDV) in high-risk patients, focusing on procedural efficacy, survival rates, and complications.
Methods: A retrospective review of 11 consecutive patients who underwent the modified bio-Bentall operation with an RDV between January 2018 and December 2022 was conducted. Kaplan-Meier survival analysis was used to determine survival rates.
Zentralbl Chir
August 2025
Institut für Herz- und Kreislaufphysiologie, Universitätsmedizin Göttingen, Göttingen, Deutschland.
Gastroparesis is a disease in which gastric emptying is significantly decreased in the absence of a mechanical obstruction of the gastric outlet. In addition to conservative or pharmacological treatment options, gastric electrical stimulation (GES) is a possible alternative therapy for refractory courses of the disease. However, the available data from randomised controlled trials on efficacy do not permit an unqualified recommendation.
View Article and Find Full Text PDFAm J Gastroenterol
July 2025
Department of Surgery, the University of Auckland, New Zealand.
Background And Aims: Chronic neurogastroduodenal disorders are heterogeneous and thought to lie on a spectrum of disease encompassing both sensory and neuromuscular pathologies. Abnormalities of interstitial cells of Cajal (ICC), a subset of which generate pacemaker signals and subsequently motility, have been implicated in their pathophysiology. We systematically reviewed the literature to pool ICC deficits observed in chronic neurogastroduodenal disorders.
View Article and Find Full Text PDFJ Laparoendosc Adv Surg Tech A
August 2025
Division of General and Foregut Surgery, Department of Biomedical Sciences for Health, IRCCS Policlinico San Donato, and University of Milano, Milan, Italy.
The prevalence of metabolic disorders and obesity is increasing worldwide. The underlying pathogenetic mechanisms include an imbalance of the autonomic nervous system secondary to a relative decrease of the parasympathetic vagal tone or increase of the sympathetic tone. Previous clinical experience with a surgically implanted gastric pacemaker for morbid obesity showed that augmenting the vagal tone effects satiety and weight control.
View Article and Find Full Text PDFWorld J Gastroenterol
May 2025
Department of General Surgery, Kansas City VA Medical Center, University of Missouri, Kansas City, MO 64128, United States.
In this article we comment on the paper by Xu describing retrospective data on endoscopic treatment outcome of esophageal gastrointestinal stromal tumors (GISTs). Esophageal GIST is a rare type of mesenchymal tumor. GISTs originate from the interstitial cells of Cajal, which are pacemaker cells involved in gut motility.
View Article and Find Full Text PDF